关于津药达仁堂集团股份有限公司 北京观韬（天津）律师事务所 2025 年第一次临时股东会的法律意见书 观意字 2025TJ000014 号 致：津药达仁堂集团股份有限公司 北京观韬（天津）律师事务所（以下简称"本所"）接受津药达仁堂集团股 份有限公司（以下简称"公司"）的委托，指派律师出席公司 2025 年第一次临 时股东会（以下简称"本次股东会"），并依据《中华人民共和国公司法》、《中 华人民共和国证券法》、《上市公司股东大会规则》等有关法律法规、规范性文 件以及《津药达仁堂集团股份有限公司章程》（以下简称"《公司章程》"）的 有关规定，出具本法律意见书。 本法律意见书仅供公司为本次股东会之目的而使用，不得被任何人用于任何 其他目的。本所在此同意，公司可以将本法律意见书作为公司本次股东会的公告 材料，随同其他信息披露资料一并公告。 本所律师按照律师行业公认的业务标准、道德规范和勤勉尽责精神，对公司 提供的文件和与本次股东会有关的事实进行了核查和验证，现就本次股东会出具 法律意见如下： 一、本次股东会的召集和召开程序 北京 · 上海 · 西安 ·成都 · 大连 · 深圳 ·济南 · 厦门 · 香港 · 天津 ...

证券代码：600329 证券简称：达仁堂 公告编号：2025-021 号 津药达仁堂集团股份有限公司 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 803 | | --- | --- | | 其中：A 股股东人数 | 783 | | 境外上市外资股股东人数（S 股） | 20 | | 2、出席会议的股东所持有表决权的股份总数（股） | 337,061,904 | | 其中：A 股股东持有股份总数 | 334,817,611 | | 境外上市外资股股东持有股份总数（S 股） | 2,244,293 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 43.769 | | 份总数的比例（%） | | | --- | --- | | 其中：A 股股东持股占股份总数的比例（%） | 43.478 | | 境外上市外资股股东持股占股份总数的比例（%） | 0.291 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 ...

Core Viewpoint - The article discusses the significant impact of centralized procurement policies on the traditional Chinese medicine (TCM) industry, highlighting the challenges and potential restructuring within the sector as it enters a new era of competition and pricing pressures [1][2][3]. Group 1: Impact of Centralized Procurement - The centralized procurement system has greatly affected the Western medicine industry, and similar pressures are now being felt in the TCM sector as it officially enters the "procurement era" [1][3]. - The scope of centralized procurement for TCM has expanded from 15 provinces to nationwide, with the number of products increasing to 45, indicating a growing impact on the industry [10][9]. - Many selected companies are pricing their products close to cost, leading to expectations of profit declines in the TCM industry by 2025 [11][12]. Group 2: Market Dynamics and Price Trends - Despite the challenges, the price of raw materials for TCM has significantly decreased this year, with the Chinese herbal medicine price index dropping over 20% from its peak [14][13]. - Some companies that won bids in the procurement process are experiencing unexpectedly high profits due to fixed hospital procurement prices, leading to optimistic sales forecasts [17]. - The average price drop for selected products in the latest procurement round was 47.38%, with some products seeing reductions as high as 69.3% [37][38]. Group 3: Industry Restructuring and Future Outlook - The TCM industry is expected to undergo significant restructuring, with a potential reduction in the number of suppliers as centralized procurement becomes more prevalent [23][24]. - The government has issued policies aimed at enhancing the quality and development of the TCM industry, indicating a push towards modernization and improved standards [25]. - The performance of TCM companies has been under pressure, with a reported 4.6% decline in total revenue and an 18.7% drop in net profit for 75 listed TCM companies in 2024 [29][28]. Group 4: Competitive Landscape - The competitive landscape is shifting, with traditional TCM giants facing challenges as their unique product strategies are tested by centralized procurement [33][40]. - Companies that previously opted out of insurance reimbursement to avoid price cuts are now facing increased pressure as more exclusive products enter centralized procurement [34][36]. - The article suggests that only companies with strong R&D capabilities, unique products, and brand advantages will thrive in the increasingly competitive environment [44][42].

Summary of Key Points Core Viewpoint - The company, Tianjin Yao Daren Tang Group Co., Ltd., is holding an earnings briefing on June 11, 2025, to provide investors with insights into its operational performance and to address investor inquiries submitted prior to the meeting [3][4][6]. Group 1: Earnings Briefing Details - The earnings briefing is scheduled for June 11, 2025, from 15:00 to 16:00 [4][8]. - Investors can submit questions via email by June 6, 2025, and the company will respond to commonly asked questions during the briefing [2][6]. - The briefing will be conducted online through the Eastmoney Roadshow platform [4][7]. Group 2: Shareholder Meeting Information - The first extraordinary general meeting of 2025 is set for June 9, 2025, at 14:00, held at the Daren Tang Building in Tianjin [11][12]. - Voting will be conducted through a combination of on-site and online methods, utilizing the Shanghai Stock Exchange's voting system [12][14]. - Shareholders must register by June 6, 2025, to participate in the meeting, with specific requirements for both individual and corporate shareholders [18][19].

证券代码：600329 证券简称：达仁堂 编号：临 2025-019 号 津药达仁堂集团股份有限公司 关于召开业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 二、说明会召开时间、地点 召开时间：2025 年 6 月 11 日（星期三）下午 15:00—16:00 召开地点：东方财富路演 1 会议召开时间：2025 年 6 月 11 日（星期三）下午 15:00—16:00 会议召开地点：东方财富路演 （http://roadshow.eastmoney.com/luyan/4754430） 会议召开方式：网络互动 投资者可于 2025 年 6 月 6 日（星期五）17:00 前预先提出所 关 注 的 问 题 并 以 电 子 邮 件 方 式 发 送 到 公 司 邮 箱 （drt600329@163.com）。公司将在说明会上对投资者普遍关 注的问题进行回答。 （http://roadshow.eastmoney.com/luyan/4754430） 召开方式：网络互动 三、参加人员 出席本次说明 ...

证券代码：600329 证券简称：达仁堂 公告编号：2025-020 号 津药达仁堂集团股份有限公司 关于召开2025年第一次临时股东大会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 6 月 9 日 14 点 00 分 召开地点：中国天津市南开区白堤路 17 号达仁堂大厦会议室 股东大会召开日期：2025年6月9日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (一)股东大会类型和届次 2025年第一次临时股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (五)网络投票的系统、起止日期和投票时间。 (七)涉及公开征集股东投票权 无 二、 会议审议事项 本次股东大会审议议案及投票股东类型 | 序号 | 议案名称 | 投票股东类型 | | --- | --- | --- | | | | 股股东 A | | 非累积投 ...

Group 1 - The company intends to transfer its 12% stake in Tianjin Sike Pharmaceutical Co., Ltd. to Haleon (China) Co., Ltd. and Haleon CH SARL, aiming to enhance cash flow and focus on core business [1][20] - The transaction price for the 4.6% stake transfer to Haleon (China) is set at approximately 1,001,137,777.78 RMB, with the total transaction value reflecting a 35% premium over the assessed asset value [1][7][20] - The transaction is not classified as a related party transaction and does not constitute a major asset restructuring as per regulations [2][20] Group 2 - Haleon (China) Co., Ltd. is a wholly foreign-owned enterprise established in 2015, with a registered capital of 195,161,000 RMB and a diverse range of business activities including medical device sales and health consulting [2][3] - Haleon CH SARL, established in 1991, operates as an investment holding company with significant assets and revenue, indicating a strong financial position [4][5] - The financial data of Tianjin Sike shows total assets of 308,784.39 million RMB and net profit of 98,165.56 million RMB for the audited period, reflecting its operational viability [5][20] Group 3 - The transaction is expected to generate approximately 1.623 billion RMB in revenue for the company, with an estimated net profit increase of around 13 billion RMB after tax implications [20] - The company plans to utilize the funds from this transaction for business expansion, including strategic acquisitions, R&D projects, and working capital [20] - The transaction aligns with the company's strategy to enhance shareholder value and does not adversely affect its operational independence [20]

证券代码：600329 证券简称：达仁堂 编号：临 2025-018 号 津药达仁堂集团股份有限公司 关于提前归还暂时补充流动资金的闲置募集资金 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 津药达仁堂集团股份有限公司（以下简称"公司"）2024 年第 三次董事会审议通过了《关于继续使用部分闲置募集资金暂时补充公 司流动资金的议案》，同意公司使用部分闲置募集资金 2.3 亿元补充 公司流动资金，使用期限自董事会批准之日起不超过 12 个月，使用 期限到期后，公司将及时、足额将该部分资金归还至募集资金专户。 相关具体内容详见 2024 年 8 月 15 日在《中国证券报》、《上海证券 报》及上海证券交易所网站（www.sse.com.cn）上刊登的《关于使用 部分闲置募集资金暂时补充流动资金的公告》（临时公告 2024-022 号）。 截至 2025 年 5 月 26 日，公司已提前将上述用于暂时补充流动资 金的募集资金全部归还至募集资金专户，并已将上述募集资金的归还 情况通知了保荐机构及保荐代表人。 特此公告。 津药 ...

津药达仁堂集团股份有限公司 2025 年第一次临时股东大会 会议资料 2025 年 6 月 9 日 目 录 现场会议召开时间：2025 年 6 月 9 日下午 2:00 会议方式：现场投票和网络投票相结合的方式 会议地点：中国天津市南开区白堤路 17 号达仁堂大厦会议室 | 1 | 公司转让所持有中美天津史克制药有限公司 12%股权暨签订《股权转 | 3 | | --- | --- | --- | | 序号 | 议案 让协议》的议案 | 页码 | 2025 年第一次临时股东大会 文件目录 2 2025 年第一次临时股东大会 议案一 议案 1：关于公司转让所持有中美天津史克制药有限公司 12%股 权暨签订《股权转让协议》的议案 公司于 2025 年 4 月 14 日召开 2025 年第二次董事会，会议审议 通过了"公司转让所持有中美天津史克制药有限公司 12%股权暨签订 《股权转让协议》的议案"。现将该议案提交公司 2025 年第一次临时 股东大会审议，议案具体情况如下： 一、交易概述 津药达仁堂集团股份有限公司（以下简称"公司"）所属参股公 司中美天津史克制药有限公司（以下简称"天津史克"）是一家中外 合资有 ...

Group 1 - The market experienced a slight adjustment last week, with the brand index closing at 1657.60 points, while several component stocks rose against the trend, including Xinlitai, Tigermed, and Stone Technology [1][2] - Xinlitai led the gains with an increase of 14.96%, followed by Tigermed at 12.48%, and Stone Technology at 11.47%. Other notable gainers included Three Squirrels and Supor, which rose by 7.69% and 6.07% respectively [2] - Since the beginning of 2025, Maimai Biological has seen a significant increase of 51.27%, with Shanghai Jahwa and Xinlitai also showing strong performance with gains of 47.96% and 47.71% respectively [3] Group 2 - Looking ahead, the market is expected to gradually shift towards a more positive trend as investors remain sensitive to favorable factors, with ongoing accumulation of positive elements supporting economic expectations and fundamentals [4] - The current market structure indicates a potential for mid-term positive performance, driven by policy support, domestic technological breakthroughs, and a favorable external environment, which may enhance liquidity in the domestic capital market [4] - In the medium to long term, opportunities may arise in sectors such as domestic demand, technology, and overseas expansion, with a focus on defensive dividend sectors and aggressive technology sectors, including internet and robotics [5]